Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Sort descending Date Recommendation Issued
Zeposia ozanimod Ulcerative colitis Reimburse with clinical criteria and/or conditions Complete
Xpovio selinexor Multiple myeloma Reimburse with clinical criteria and/or conditions Complete
Scemblix asciminib Philadelphia chromosome-positive chronic myeloid leukemia Reimburse with clinical criteria and/or conditions Complete
Tecentriq atezolizumab Small Cell Lung Cancer Reimburse with clinical criteria and/or conditions Complete
Rozlytrek entrectinib Extracranial solid tumours with NTRK gene fusion Reimburse with clinical criteria and/or conditions Complete
Vraylar cariprazine Bipolar Disorder Do not reimburse Complete
Saphnelo anifrolumab Systemic lupus erythematosus Reimburse with clinical criteria and/or conditions Complete
Vabysmo faricimab Macular degeneration, age-related Reimburse with clinical criteria and/or conditions Complete
Doptelet avatrombopag Chronic immune thrombocytopenia (ITP) Active
Keytruda pembrolizumab Triple-negative breast cancer Reimburse with clinical criteria and/or conditions Complete